Overview

* Profound Medical ( PROF ) Q3 revenue up 87% yr/yr, beating analyst expectations

* Gross margin increased 1,119 basis points to 74.3% in Q3-2025

* Company reported a net loss of $8 mln, improved from last year

Outlook

* Profound Medical ( PROF ) expects to reach at least 75 TULSA-PRO installs by year-end

Result Drivers

* SALES PIPELINE - Profound's growing TULSA-PRO sales pipeline contributed to revenue growth

* MANUFACTURING EFFICIENCY - Gross margin expansion attributed to higher manufacturing efficiency

* STRATEGIC AGREEMENTS - New distribution agreements expected to support growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $5.30 $4.72

Revenue mln mln (4

Analysts

)

Q3 EPS -$0.26

Q3 Net -$8 mln

Income

Q3 $12.80

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)